Folino-Gallo Pietro, Montilla Simona, Bruzzone Mario, Martini Nello
Centre for Studies, Italian Medicines Agency (AIFA), Rome, Italy.
Eur J Health Econ. 2008 Aug;9(3):305-10. doi: 10.1007/s10198-008-0114-5.
In Italy the price setting of medicines reimbursed by the National Health Service is regulated at the central level by AIFA, the national regulatory authority. Prices of non reimbursed medicines are indeed freely established, with some limitations, by pharmaceutical companies. To contain pharmaceutical expenditure and rationalise the whole sector the following measures have been introduced in the past years: a threshold to public pharmaceutical expenditure (PPE); a reference price system (RPS) for off-patent medicines; a pay-back mechanism as an alternative to price cut. In 2008 Italy launched a reform of the pharmaceutical expenditure governance system with the aim to introduce stability and promote development and competitiveness in the pharmaceutical sector.
在意大利，由国家医疗服务体系报销的药品价格由国家监管机构意大利药品管理局（AIFA）在中央层面进行调控。未报销药品的价格实际上由制药公司在有一定限制的情况下自由确定。为控制药品支出并使整个行业合理化，过去几年采取了以下措施：设定公共药品支出（PPE）的上限；针对专利过期药品的参考价格体系（RPS）；作为降价替代方案的回款机制。2008年，意大利启动了药品支出治理体系改革，旨在为制药行业引入稳定性并促进其发展与竞争力。
